ASCO analyst and investor meeting

1 June 2013, Chicago, IL
Cautionary Statement Regarding Forward-Looking Statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any delay in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the impact of failing to attract and retain key personnel and to successfully engage with our employees and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation. Nothing in this presentation should be construed as a profit forecast.
<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30pm</td>
<td>Welcome and Introduction</td>
<td></td>
</tr>
<tr>
<td>6:35pm</td>
<td>Olaparib update</td>
<td>Jane Robertson VP Global Product Development</td>
</tr>
<tr>
<td>6:45pm</td>
<td>Selumetinib update</td>
<td>Donna Francher VP Global Product Development</td>
</tr>
<tr>
<td>6:55pm</td>
<td>Q&amp;A</td>
<td>Jane Robertson Donna Francher Susan Galbraith</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Head of Innovative Medicines Oncology IMED</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ed Bradley Head of MedImmune Oncology IMED</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antoine Yver Head of Oncology Global Medicines</td>
</tr>
<tr>
<td>7:30pm</td>
<td>Close</td>
<td></td>
</tr>
</tbody>
</table>
Olaparib update

Jane Robertson
VP Global Product Development
Study 19: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer

- Patients were randomized after response to platinum-based chemotherapy
- Interim OS analysis (38% maturity): HR=0.94; 95% CI 0.63–1.39; P=0.75

HR, hazard ratio; OS, overall survival; PFS, progression-free survival
*Patients were treated until disease progression*
Methods: BRCAm testing

Germline BRCAm (gBRCAm) status was determined retrospectively in an additional 121 patients (218 in total)

• The diagnostic assay (Myriad Genetics) used blood samples collected before randomization from consenting patients

Since patients without an inherited gBRCAm can develop somatic mutations, tumour BRCAm (tBRCAm) status was also determined in 209/265 patients

• Archival tumour samples were analyzed by Foundation Medicine
PFS by BRCAm status

Events: total pts (%)
Median PFS, months

<table>
<thead>
<tr>
<th>BRCAm (n=136)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olaparib</td>
</tr>
<tr>
<td>26:74 (35.1)</td>
</tr>
<tr>
<td>11.2</td>
</tr>
</tbody>
</table>

HR=0.18
95% CI (0.11, 0.31); P<0.00001

82% reduction in risk of disease progression or death with olaparib
OS in BRCAm patients

Deaths: total pts (%)

- Median OS, months

<table>
<thead>
<tr>
<th></th>
<th>Olaparib</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCAm (n=136)</td>
<td>37:74 (50.0)</td>
<td>34:62 (54.8)</td>
</tr>
<tr>
<td></td>
<td>34.9</td>
<td>31.9</td>
</tr>
<tr>
<td>HR</td>
<td>0.74</td>
<td>95% CI (0.46, 1.19)</td>
</tr>
<tr>
<td>P</td>
<td>0.208</td>
<td></td>
</tr>
</tbody>
</table>

OS in BRCAwt patients: HR=0.98; 95% CI 0.62–1.55; P=0.946

- Median OS: olaparib, 24.5 months; placebo, 26.2 months

14/62 (22.6%) placebo patients switched to a PARP inhibitor
Olaparib development plan 2013

BRCA-mutated ovarian cancer
• Platinum-sensitive, relapsed maintenance study with ENGOT
• High-risk, first-line ovarian maintenance with GOG

BRCA-mutated breast cancer
• Metastatic disease with Breast Cancer Alliance
• Neoadjuvant (combination with paclitaxel) with Breast International Group
• Adjuvant treatment post-chemotherapy with Breast International Group

Gastric cancer
• Second-line combination with paclitaxel: Asia study

Prostate cancer
• Phase II combination with abiraterone
• Phase I combination with AZD5363 (AKTi)

ENGOT, European Network of Gynaecological Oncological Trial Groups; GOG, Gynecologic Oncology Group
Selumetinib update

Donna Francher
VP Global Product Development
Monotherapy activity in uveal melanoma (GNAQ)

Scientific / Clinical Context

- In contrast to melanomas, uveal melanomas rarely exhibit NRAS / BRAF activation
- Commonly possess mutation of GNAQ. Provides an alternate route to MEK-ERK activation
- No effective standard of care
- Trametinib did not warrant taking forward after single-arm study

Implications

- This is the largest Phase II trial in uveal melanoma
- We are discussing options for moving forward

Van Raamsdonk et al., Nature 2009;457:599-602
Accelerating multiple opportunities with selumetinib

Starting pivotal trials 2013

- Effective and well-tolerated as monotherapy
- Induces ‘re-differentiation’ in thyroid cancer
- Active in combination with chemo in multiple tumour types
- Opportunity to lead in high unmet need indications with MEK-dependence
- 2H13 trial starts – 2L KRASm NSCLC (Phase III – planned); thyroid (pivotal Phase IIB)

Selumetinib in MEK-driven tumours

Images: NF – Klaus D. Peter, Gummersbach, Germany (Creative Commons license); GI – courtesy of Deirdre Cohen and Howard Hochster, Yale University, USA; Lung – courtesy of E. Cortell, Harvard Vanguard Medical Associates, USA

NSCLC – non-small cell lung cancer
Selumetinib combination with chemo in NSCLC

Active in combination with chemotherapy

- High and durable response rate in segment with poor response to docetaxel alone
- Improved PFS
- Tolerated in combination with doublet chemotherapy
- KRASm NSCLC opportunity – ~25K 2nd-line; ~45K 1st-line
- Pivotal study to start October 2013

Evidence in 2nd-line KRASm NSCLC

<table>
<thead>
<tr>
<th></th>
<th>Selumetinib + Docetaxel (N=43)</th>
<th>Placebo + Docetaxel (N=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Response</strong></td>
<td>16 (37%)</td>
<td>0</td>
</tr>
<tr>
<td><strong>Non-response</strong></td>
<td>27 (63%)</td>
<td>40 (100%)</td>
</tr>
</tbody>
</table>

Median PFS = 5.3 vs. 2.1 months
Trend to increased median OS (9.4 vs. 5.2 months)

Originally presented at ASCO 2012

1. G7 only – Kantar Health, internal AZ estimates
2. Jänne et al., Lancet Oncol 2013; 14:38-47
3. Selumetinib 75 mg BD; docetaxel 75 mg/m²
4. HR 0.58, 80% CI (0.42, 0.79), p = 0.0138
PFS – progression free survival
Q&A